Novartis Reports Weaker Q1 Results Due to Generic Competition
Novartis (NVS) reported weaker-than-expected first-quarter results, with profit missing estimates and revenue declining due to increased generic competition. Net sales fell to $13.1 billion, a 1% decrease year-over-year, with volume growth offset by pricing pressures.
Tickers: $NVS
Topics: Earnings Generic Competition Pharmaceutical Industry Profit Miss Revenue Decline